People with HIV experience earlier impairments in physical function compared to people in the general population. They also exhibit an earlier presentation and more rapid development of frailty, a multisystemic syndrome of aging characterized by reduced activity, fatigue, slowness, weakness, and weight loss. While exercise can improve physical function in people with HIV, it is less effective in doing so than in the general population and is difficult to sustain in the long-term.
The goal of this clinical trial is to learn whether the medication tesamorelin will improve physical function and muscle health in adults with HIV when combined with exercise. Tesamorelin is a growth hormone-releasing hormone analogue that is FDA-approved to treat abdominal fat accumulation in people with HIV. While tesamorelin has also been shown to increase muscle mass and improve measures of muscle health, its effects on physical performance and muscle strength have not yet been evaluated.
During a 24-week intervention phase, half of participants will be randomly assigned to receive tesamorelin and half of participants will be randomly assigned to receive placebo (a look-alike substance that contains no drug). All participants also will engage in a home-based exercise intervention supervised by an exercise coach. During a subsequent 24-week extension phase, individuals will be monitored off study drug and supervised exercise, and be encouraged to continue to exercise independently.
The investigators will investigate effects of tesamorelin on physical function, muscle mass and quality, quality of life, and exercise adherence and self-efficacy. They also will evaluate whether effects of tesamorelin are maintained following treatment cessation. This study may identify an important strategy to improve how individuals aging with HIV function and feel with potential applications to other patient populations.

Start Date01 Mar 2025

Sponsor / Collaborator

The General Hospital Corp.

[+1]

NCT03375788

/ Active, not recruitingPhase 2IIT

Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk

Nonalcoholic fatty liver disease (NAFLD) is common in individuals with obesity and is a significant threat to public health, because it can lead to impaired liver function and liver failure. Growth hormone is a hormone produced in the pituitary gland that helps regulate metabolism and growth. Individuals with obesity, on average, secrete less growth hormone than individuals without obesity. There are data to suggest that growth hormone may help to reduce the amount of fat in the liver, and may also reduce inflammation in the liver, both of which would be helpful to individuals with NAFLD. The purpose of this study is to investigate whether treatment with a drug called tesamorelin, which is a growth hormone releasing hormone analogue, will decrease liver fat and improve liver inflammation and scarring in obese individuals with NAFLD.

Start Date17 Jan 2019

Sponsor / Collaborator

The General Hospital Corp.

NCT03226821

/ RecruitingPhase 4IIT

Body Composition and Adipose Tissue in HIV Lipodystrophy: Effects of Tesamorelin Therapy

In this study, the investigators will examine the effect of therapy with the Growth Hormone Releasing Hormone (GHRH) analog tesamorelin on body composition in patients with HIV lipodystrophy and central adiposity. This study is a single arm prospective study of tesamorelin therapy of patients with HIV lipodystrophy. Subjects will do body composition testing, adipose tissue biopsy, metabolic rate measurements and insulin sensitivity assessment before, 6 and 12 months after daily injections of tesamorelin 2 mg by subcutaneous injection.

Start Date07 Feb 2018

Sponsor / Collaborator

Columbia University

[+1]

100 Clinical Results associated with Tesamorelin Acetate

100 Translational Medicine associated with Tesamorelin Acetate

100 Patents (Medical) associated with Tesamorelin Acetate

104

Literatures (Medical) associated with Tesamorelin Acetate

01 Oct 2024·AIDS

Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors

Article

Author: Toribio, Mabel ; Hadigan, Colleen M ; Fourman, Lindsay T. ; Johnson, Julia E. ; Arpante, Allison K. ; Ockene, Mollie W. ; Russo, Samuel C. ; Lee, Hang ; Erlandson, Kristine M ; Johnson, Julia E ; Hadigan, Colleen M. ; Grinspoon, Steven K. ; Stanley, Takara L. ; Arpante, Allison K ; Ockene, Mollie W ; Russo, Samuel C ; Grinspoon, Steven K ; Stanley, Takara L ; Fourman, Lindsay T

Objective:Tesamorelin is the only FDA-approved therapy to treat abdominal fat accumulation in people with HIV (PWH). Phase III clinical trials were conducted prior to the introduction of integrase inhibitors (INSTIs), which are now a mainstay of HIV antiretroviral therapy.Design:We leveraged a randomized double-blind trial of 61 PWH and metabolic dysfunction-associated steatotic liver disease to evaluate the efficacy and safety of tesamorelin 2 mg once daily vs. identical placebo among participants on INSTI-based regimens at baseline.Methods:In the parent clinical trial, visceral fat cross-sectional area, hepatic fat fraction, and trunk-to-appendicular fat ratio were quantified using magnetic resonance imaging, proton magnetic resonance spectroscopy, and dual-energy x-ray absorptiometry, respectively, at baseline and 12 months. Metabolic and safety outcomes were compared between treatment arms.Results:Among 38 participants on INSTI-based regimens at baseline, 15 individuals on tesamorelin and 16 individuals on placebo completed the 12-month study. Tesamorelin led to significant declines in visceral fat (median [interquartile range]: −25 [−93, −2] vs. 14 [3, 41] cm2, P = 0.001), hepatic fat (−4.2% [−12.3%, −2.7%] vs. −0.5% [−3.9%, 2.7%], P = 0.01), and trunk-to-appendicular fat ratio (−0.1 [−0.3, 0.0] vs. 0.0 [−0.1, 0.1], P = 0.03). Tesamorelin was well tolerated with a similar frequency of adverse events, including hyperglycemia, between groups.Conclusions:The current analysis provides the first dedicated data on the efficacy and safety of tesamorelin among PWH on INSTI-based regimens. Despite the association of INSTI use with weight gain and adipose tissue dysfunction, tesamorelin had beneficial effects on body composition with no exacerbation of glycemic control.

12 Aug 2024·Topics in antiviral medicine

CROI 2024: Neuropsychiatric Complications in People With HIV.

Review

Author: Letendre, Scott L ; Corley, Michael J ; Nightingale, Sam

The 2024 Conference on Retroviruses and Opportunistic Infections featured new and impactful findings about neuropsychiatric complications in people with HIV and other infections. Reports included new evidence from low- and middleincome countries, HIV persistence in the central nervous system, aging-related complications (including cerebrovascular disease), additional data relevant to pathogenesis, and therapeutics. Also included were new evidence of active HIV RNA transcription in cells from cerebrospinal fluid and the brain during virally suppressive antiretroviral therapy as well as links between neuropsychiatric complications or brain imaging findings in people with HIV and a) carotid artery inflammation and cerebrovascular disease, b) Alzheimer's disease genetic risk, c) social determinants of health, including exposure to pollution, and d) epigenetic aging. New therapeutic findings were presented on the cerebrospinal fluid inhibitory quotient, the effects of polypharmacy, and clinical trials of tesamorelin and telmisartan. This review summarizes these and other new findings and highlights new research directions for the neuro-HIV field.

01 Dec 2023·Analytical biochemistry

Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.

Article

Author: David, Victor ; Cristea, Cătălina-Diana ; Radu, Mihai ; Toboc, Ani ; Stan, Cristina

The use of growth hormone-releasing hormones (GHRHs) is prohibited in sports according to the regulations of the World Anti-Doping Agency (WADA). Considering the complexity of urine samples and the low concentrations at which these analytes should be detected, analyzing GHRHs is a challenging task. In most of the studies, GHRHs are analyzed using UHPLC-HRMS with an orbitrap. The present developed and validated method for some GHRHs (tesamorelin, CJC-1295, sermorelin (GRF 1-29), sermorelin (3-29)-NH₂, somatorelin) is based on the triple quadrupole UHPLC/MS-MS method with solid phase extraction (SPE) with weak cation exchange and is able to detect concentrations as low as 0.2 ng/mL (LOD), a limit of quantification (LOQ) at 0.6 ng/mL, and linearity across the range of 0.1 ng/mL to 1.2 ng/mL. The present method developed by our doping control laboratory was validated according to WADA technical documents for selectivity, limit of detection (LOD), carryover, reliability of detection, stability and recovery. The results show that the method has adequate recoveries and sensitivity, hence, it can be employed for routine screening in anti-doping laboratories.

News (Medical) associated with Tesamorelin Acetate

14 Feb 2025

·www.globenewswire.com

Theratechnologies Resumes Distribution of EGRIFTA SV®

MONTREAL, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care, today announced that it has resumed distribution of EGRIFTA SV® (tesamorelin for injection), following correspondence from the U.S. Food and Drug Administration (FDA) that allows the Company to release two recently manufactured batches of EGRIFTA SV®. The product is ready for immediate shipment to network pharmacies. “We remain committed to providing EGRIFTA SV® to people with HIV and we truly appreciate the FDA’s collaboration to get the treatment back to the patients who rely on it,” said Christian Marsolais, PhD, Senior Vice President and Chief Medical Officer at Theratechnologies. Review of the Company’s Prior Approval Supplement by the FDA is ongoing with an action goal date of April 18, 2025. EGRIFTA SV® is distributed in the United States only. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and X. Forward-Looking Information This press release contains forward-looking statements and forward-looking information (collectively, the “Forward-Looking Statements”) within the meaning of applicable securities laws, that are based on management’s beliefs and assumptions and on information currently available to it. You can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “promising”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate”, or the negatives of these terms, or variations of them. The Forward-Looking Statements contained in this press release include, but are not limited to, statements regarding: (i) the review of the Prior Approval Supplement (PAS) within the timelines announced herein; and (ii) the provision of EGRIFTA SV® to people with HIV. Although the Forward-Looking Statements contained in this press release are based upon what the Company believes are reasonable assumptions in light of the information currently available, investors are cautioned against placing undue reliance on these statements since actual results may vary from the Forward-Looking Statements contained in this press release. Certain assumptions made in preparing the Forward-Looking Statements include that: (i) the PAS will be approved by the FDA; (ii) the review of the PAS will be completed within the timelines disclosed herein; (iii) current market demand for EGRIFTA SV® has not been adversely impacted by the drug shortage; and (iv) the Company’s third party manufacturer will be able to continue the manufacture of EGRIFTA SV® to meet patients demand . Forward-Looking Statements assumptions are subject to a number of risks and uncertainties, many of which are beyond the Company’s control, that could cause actual results to differ materially from those that are disclosed in or implied by such Forward-Looking Statements. These risks and uncertainties include, but are not limited to: (i) FDA’s review of the PAS not being completed by April 18, 2025; (ii) non-approval of the PAS; (iii) issuance of questions as part of the PAS review by the FDA resulting in delays in completing the PAS review and resulting in delays beyond April 18, 2025, to release additional batches of EGRIFTA SV®, if need be; (iv) issuance of a complete response letter following the filing of the PAS as a result of the manufacturing site being classified as Official Action Indicated preventing the Company from releasing additional batches of EGRIFTA SV®, unless new authorizations similar to the one announced herein are obtained from the FDA; and (v) a decrease in demand for EGRIFTA SV® due to the recent shortage adversely impacting the resumption of the commercialization of EGRIFTA SV®;. The Company refers current and potential investors to the “Risk Factors” section of the Company’s Form 20-F dated February 21, 2024 available on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov under Theratechnologies’ public filings. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-Looking Statements reflect current expectations regarding future events and speak only as of the date of this press release and represent the Company’s expectations as of that date. The Company undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law. Contacts: Media inquiries:Julie SchneidermanSenior Director, Communications & Corporate Affairscommunications@theratech.com1-514-336-7800 Investor inquiries:Joanne ChoiSenior Director, Investor Relationsjchoi@theratech.com1-551-261-0401

Drug Approval

10 Jan 2025

·www.globenewswire.com

World Orphan Drug Alliance expands to Canada and full LATAM region, completing the first truly global commercialization offering

By adding Canada and the entire Latin America region, including Mexico, WODA completes its full global commercialization offering for rare and specialty therapies.With two new members - Innovative Medicines Group and Theratechnologies - WODA now provides access to over 210 million rare disease patients. MONTREAL and MONTEVIDEO, Uruguay, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The World Orphan Drug Alliance (WODA), a global alliance of commercial distributors dedicated to providing access to treatments for rare diseases and specialty medicines in complex markets worldwide, has expanded its reach to include Canada and all of Latin America (LATAM). The addition of two new members - Theratechnologies Inc. for Canada and Innovative Medicines Group (IMG) for LATAM - brings the total number of countries covered by WODA to 158 and extends its reach to 210 million rare disease patients. The alliance now consists of 12 members, each being expert for the region covered. This expansion effectively completes WODA's ambition to provide global access to rare disease treatments. “With a new partner in LATAM and the addition of Canada, we are thrilled to become the only truly global-for-local platform," said Patrick Jordan, Chairman of WODA. "Canada not only gives our partners a footprint in North America, but with Theratechnologies’ operations in the U.S., they can be a U.S. solution as well. With IMG, we have a broader coverage of LATAM, including Mexico." Headquartered in Montreal, Theratechnologies was one of WODA’s first partners with the distribution of EGRIFTA SV® globally. They have recently broadened their portfolio, announcing an exclusive licensing deal with Ionis Pharmaceuticals for two assets in Canada. With a strong history of collaboration, Theratechnologies is a natural partner for WODA in Canada. WODA has also gained a strong new member in IMG, introducing a new platform for LATAM. IMG allows for a turnkey solution in the stalwart markets of Brazil, Argentina, and Colombia, and with a strong regional footprint ensures coverage across the rest of Latin America, including Mexico. Based in Montevideo, Uruguay, the team has a proven track record of serving rare disease patients throughout the region. The Alliance now provides a broad outreach with a local focus through thirteen separate entities: Specialised Therapeutics (Australia, New Zealand and Southeast Asia), Medis (Central and Eastern Europe & Nordics), Path Pharma (Greece, Cyprus, Malta), CTS (Israel), Innovative Medicines Group (Latin America), Vector Pharma (Middle East, North Africa, and Turkey), Orpharm (Russia and the CIS region), EffRx (Switzerland), Veld (Africa), Nxera (Japan, South Korea), Theratechnologies (Canada) and its boutique consultancy partner Decisive Consulting. About WODAThe World Orphan Drug Alliance (WODA) is a global alliance of commercial distributors focused on providing access to treatments for rare diseases and specialty medicines in complex markets around the world. WODA aims to provide comprehensive support to pharmaceutical and biotech companies with rare disease, oncology, and highly specialized therapeutics portfolio, starting from Named Patient Programs through to full commercialization. More about WODA: www.woda-alliance.com Media contact: Tina Vojnovic, tina.vojnovic@woda-alliance.com+386 41 744 735

License out/inOrphan Drug

09 Jan 2025

·www.globenewswire.com

Theratechnologies Provides Update on EGRIFTA SV® Supply

MONTREAL, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that a shortage of EGRIFTA SV® (tesamorelin for injection) will occur at the patient level in mid-January 2025, following a voluntary shutdown of the contract manufacturing facility in 2024. While the Company is aware of remaining inventory of EGRIFTA SV® in certain pharmacies throughout the United States, several pharmacies have reported stockouts. Theratechnologies filed a required Prior Approval Supplement (PAS) to the U.S. Food and Drug Administration (FDA) on December 18, 2024. The Company subsequently submitted questions as part of a Type D meeting request concerning the status of two recently manufactured batches of EGRIFTA SV®, which are waiting to be released to pharmacies. The FDA confirmed that it would respond to the Company’s questions in writing no later than February 8, 2025. “We remain committed to people with HIV who rely on EGRIFTA SV®, as it is the only FDA-approved medicine of its kind, and we will continue to work with the FDA to expedite the release of the new batches for patients,” said Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer at Theratechnologies. The Company will update the market on any further material developments. EGRIFTA SV® is distributed in the United States only. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and Twitter. Forward-Looking Information This press release contains forward-looking statements and forward-looking information (collectively, the “Forward-Looking Statements”) within the meaning of applicable securities laws, that are based on management’s beliefs and assumptions and on information currently available to it. You can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “promising”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate”, or the negatives of these terms, or variations of them. The Forward-Looking Statements contained in this press release include, but are not limited to, statements regarding: (i) the time period related to the availability of EGRIFTA SV® to patients; (ii) the date by which the FDA will respond to the Company’s questions following its request to have a Type D meeting; and (iii) the timelines related to the potential release of the recently manufactured batches of EGRIFTA SV®. Although the Forward-Looking Statements contained in this press release are based upon what the Company believes are reasonable assumptions in light of the information currently available, investors are cautioned against placing undue reliance on these statements since actual results may vary from the Forward-Looking Statements contained in this press release. Certain assumptions made in preparing the Forward-Looking Statements include that: (i) the FDA will provide answers to the questions asked by the Company by February 8, 2025; (ii) the responses to the questions asked by the Company will confirm that the Company is able to release the recently manufactured batches of EGRIFTA SV® or will confirm that the review of the PAS will be completed prior to the expiry of a four-month period; (iii) current market demand for EGRIFTA SV® will remain unaffected; (iv) the shortage of EGRIFTA SV® will not adversely impact the financial conditions of the Company; and (v) the Company will be able to negotiate waivers of defaults with its secured creditors to the extent the drug shortage period results in defaults under its credit agreements. Forward-Looking Statements assumptions are subject to a number of risks and uncertainties, many of which are beyond the Company’s control, that could cause actual results to differ materially from those that are disclosed in or implied by such Forward-Looking Statements. These risks and uncertainties include, but are not limited to: (i) delays in responding to the Company’s questions beyond February 8, 2025; (ii) refusal by the FDA to release the recently manufactured batches of EGRIFTA SV® until the PAS review is completed; (iii) FDA’s review of the PAS not being completed before April 18, 2025; (iv) non-approval of the PAS; (v) issuance of questions as part of the PAS review by the FDA resulting in delays in completing the PAS review and resulting in delays beyond April 18, 2025 to release the recently manufactured batches of EGRIFTA SV®; (vi) issuance of a complete response letter following the filing of the PAS as a result of the manufacturing site being classified as Official Action Indicated preventing the Company from releasing the recently manufactured batches of EGRIFTA SV®; (vii) a decrease in demand for EGRIFTA SV® due to its shortage potentially adversely impacting the resumption of the commercialization of EGRIFTA SV®; (viii) losses of key employees due to the shortage; and (ix) defaults under the covenants of the credit agreements resulting from the shortage. The Company refers current and potential investors to the “Risk Factors” section of the Company’s Form 20-F dated February 21, 2024 available on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov under Theratechnologies’ public filings. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-Looking Statements reflect current expectations regarding future events and speak only as of the date of this press release and represent the Company’s expectations as of that date. The Company undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law. Contacts: Investor inquiries:Joanne ChoiSenior Director, Investor Relationsjchoi@theratech.com1-551-261-0401 Media inquiries:Julie SchneidermanSenior Director, Communications & Corporate Affairscommunications@theratech.com1-514-336-7800

Drug ApprovalAccelerated Approval

100 Deals associated with Tesamorelin Acetate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Tesamorelin Acetate	H01AC06	DB08869

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
HIV Infections	United States	Theratechnologies, Inc.	10 Nov 2010
Lipodystrophy	United States	Theratechnologies, Inc.	10 Nov 2010

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Fibrosis, Liver	Phase 2	Canada	Theratechnologies Europe Ltd.	30 Jan 2022
Muscular Atrophy	Preclinical	-	Theratechnologies, Inc.	01 Sep 2011
Pulmonary Disease, Chronic Obstructive	Preclinical	-	Theratechnologies, Inc.	01 Sep 2011
HIV Seropositivity	Discovery	Canada	Theratechnologies, Inc.	01 May 2008
HIV-Associated Lipodystrophy Syndrome	Discovery	United States	Theratechnologies, Inc.	01 Jun 2005
HIV-Associated Lipodystrophy Syndrome	Discovery	Canada	Theratechnologies, Inc.	01 Jun 2005
Diabetes Mellitus, Type 2	Discovery	-	Theratechnologies, Inc.	01 Feb 2002

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


GlobeNewswire Manual	Phase 3	Cardiovascular Diseases \| HIV Infections	-	Tesamorelin	dxkmdgnrow(osqljvmfwq) = emozyxmenc jpgrpoclie (ijlxcatgtu, -0.89 to 0.05)	Positive	17 Oct 2024
ENDO2021	Not Applicable	Metabolic dysfunction-associated steatotic liver disease Maintenance C-C Motif Chemokine Ligands 3 \| interleukin-8 \| interleukin-10 ... View more	61	Tesamorelin	djwpcobjvf(usqgpvptaw) = qngwdahskf odhkvjqysp (mzyzhdfzdh ) View more	Positive	03 May 2021
NCT02196831 (CTgov)	Not Applicable	Nonalcoholic Steatohepatitis \| HIV Infections	61	tesamorelin (Tesamorelin)	uhlpadroqd(ragaqodfpn) = xqkvhhbajc cxrcgyjkfb (biehphzefd, fxptrrfqkn - tlwdxeueyn) View more	-	13 Jan 2020
				Placebo (Placebo)	uhlpadroqd(ragaqodfpn) = rjntunlfbc cxrcgyjkfb (biehphzefd, oedogrpehm - cnzwcvvfot) View more
NCT00608023 \| NCT00123253 (Pubmed)	Phase 3	HIV Infections	806	Tesamorelin	(znsworvnkn) = xiezspdntp hhejwmgxpm (edndhbqdpd ) View more	-	23 Oct 2017
				Placebo	(znsworvnkn) = ykwqpuavuz hhejwmgxpm (edndhbqdpd ) View more
NCT00807365 (PP2, CTgov)	Phase 2	-	5	GHRH	ldfpsplxpd(hrflwielcq) = tvbydoldsc romzxpatxy (gbvblquhim, jtgbzwjfrb - tlegptzyof) View more	-	27 Apr 2017
NCT01263717 (CTgov)	Not Applicable	HIV-Associated Lipodystrophy Syndrome	54	tesamorelin (Tesamorelin)	xwjhmrqkcz(gmqmtfletm) = obmuaijaik ctybqmlaon (dfqpqmzrya, qfymyzieky - cfdlkfgxnj) View more	-	13 Oct 2014
				placebo (Placebo (Inactive Injection))	xwjhmrqkcz(gmqmtfletm) = abvhovevkp ctybqmlaon (dfqpqmzrya, eeyvmvgxxq - obihwtvqux) View more
NCT01263717 (Pubmed \| JAMA)	Not Applicable	HIV Infections	50	Tesamorelin 2 mg	xzauejaoxj(gapcmqkoog) = yovthaozjr zqlavcdewk (uscqjpqgej ) View more	-	30 Jul 2014
				Placebo	xzauejaoxj(gapcmqkoog) = ykmoxuyyzs zqlavcdewk (uscqjpqgej ) View more
NCT01388920 (CTgov)	Phase 2	Pulmonary Disease, Chronic Obstructive \| Muscular Atrophy	3	Tesamorelin (Tesamorelin 2 mg)	lxlkzkkazr(uraxuimqph) = ddytgnanyw swsxpjapda (ssamxjeypd, dsjwewzmaj - mmtnzxxrlx) View more	-	07 May 2014
				Tesamorelin (Tesamorelin 3 mg)	lxlkzkkazr(uraxuimqph) = fiprulzrwe swsxpjapda (ssamxjeypd, kparfurlbb - yglrxmxdza) View more
NCT00795210 (CTgov)	Not Applicable	Lipodystrophy \| HIV Infections	25	growth hormone (GH 6mcg/kg/d)	rnxggulvae(nzsrrsjqbm) = uxuxxcmmns qgwzgvbuqf (ytbbwhqaqm, hgoxounznh - yykuslfinn) View more	-	08 Jan 2014
				growth hormone (GH 2mg Daily)	rnxggulvae(nzsrrsjqbm) = mbhggtrfzd qgwzgvbuqf (ytbbwhqaqm, jitevzgcxc - vaxqlvaynu) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis